Home / Cardiovascular system / Quinapril
ATC C09AA06 · Ace Inhibitors, Plain
Quinapril shortage
As of 2 Nov 2026, Quinapril has a reported shortage in 2 of the 15 countries we track (United States, Canada), covering 24 products from 6 companies.
Countries2/15
Products24packs or presentations
Companies63 listed
Short since9 Mar 20215.7 years ago
Earliest returnnot givencompany estimate
Main reasonManufacturing problem
United States16 products shortCanada8 products shortGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechiaNo reported shortageNorwayNo reported shortageSwedenNo reported shortageJapanNo reported shortageAustraliaNo reported shortage
Timeline
United StatesCanada
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Which companies are short
products short, all countriesListed: Aurobindo AUROPHARMA · NSE, Lupin LUPIN · NSE, Pfizer PFE · NYSE
Compared with similar medicines
ATC group C09AA · Ace Inhibitors, PlainAffected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09) | Solco Healthcare US, LLC | 19 Jan 2023 | not given | Active ingredient shortage Shortage of an active ingredient |
| US | Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90) | Chartwell Molecular Holdings LLC | 19 Jan 2023 | not given | Not stated |
| US | Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90) discontinuation | Aurobindo Pharma USA | 19 Jan 2023 | not given | Manufacturing problem Discontinuation of the manufacture of the drug |
| US | Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90) discontinuation | Aurobindo Pharma USA | 19 Jan 2023 | not given | Manufacturing problem Discontinuation of the manufacture of the drug |
| US | Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09) | Lupin Pharmaceuticals, Inc. | 19 Jan 2023 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| US | Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09) | Solco Healthcare US, LLC | 19 Jan 2023 | not given | Active ingredient shortage Shortage of an active ingredient |
| US | Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90) | Chartwell Molecular Holdings LLC | 19 Jan 2023 | not given | Not stated |
| US | Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09) | Lupin Pharmaceuticals, Inc. | 19 Jan 2023 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| US | Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09) | Solco Healthcare US, LLC | 19 Jan 2023 | not given | Active ingredient shortage Shortage of an active ingredient |
| US | Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90) | Chartwell Molecular Holdings LLC | 19 Jan 2023 | not given | Not stated |
| US | Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90) discontinuation | Aurobindo Pharma USA | 19 Jan 2023 | not given | Manufacturing problem Discontinuation of the manufacture of the drug |
| US | Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09) | Lupin Pharmaceuticals, Inc. | 19 Jan 2023 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| US | Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09) | Solco Healthcare US, LLC | 19 Jan 2023 | not given | Active ingredient shortage Shortage of an active ingredient |
| US | Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60) | Chartwell Molecular Holdings LLC | 19 Jan 2023 | not given | Not stated |
| US | Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90) discontinuation | Aurobindo Pharma USA | 19 Jan 2023 | not given | Manufacturing problem Discontinuation of the manufacture of the drug |
| US | Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09) | Lupin Pharmaceuticals, Inc. | 19 Jan 2023 | not given | Manufacturing problem Requirements related to complying with good manufacturing practices |
| CA | APO-QUINAPRIL (100 BTL) | APOTEX INC | 9 Mar 2021 | not given | Active ingredient shortage Shortage of an active ingredient |
| CA | APO-QUINAPRIL (100 BTL) | APOTEX INC | 30 Jul 2021 | not given | Active ingredient shortage Shortage of an active ingredient |
| CA | ACCUPRIL 5MG TAB (1x90 Bottle) | PFIZER CANADA ULC | 30 Sep 2021 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | APO-QUINAPRIL (100 BTL) | APOTEX INC | 29 Oct 2021 | not given | Active ingredient shortage Shortage of an active ingredient |
| CA | APO-QUINAPRIL (100 BTL) | APOTEX INC | 29 Nov 2021 | not given | Active ingredient shortage Shortage of an active ingredient |
| CA | ACCUPRIL TAB 10MG (1x90 BTL) | PFIZER CANADA ULC | 19 Apr 2022 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | ACCUPRIL TAB 20MG (1x90 BTL) | PFIZER CANADA ULC | 19 Apr 2022 | not given | Manufacturing problem Disruption of the manufacture of the drug |
| CA | ACCUPRIL TAB 40MG (1x90 BTL) | PFIZER CANADA ULC | 19 Apr 2022 | not given | Manufacturing problem Disruption of the manufacture of the drug |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.